Lumos Pharma (LUMO)
(Delayed Data from NSDQ)
$3.92 USD
+0.16 (4.26%)
Updated Sep 24, 2024 04:00 PM ET
3-Hold of 5 3
F Value C Growth F Momentum F VGM
Price, Consensus and EPS Surprise
LUMO 3.92 +0.16(4.26%)
Will LUMO be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for LUMO based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for LUMO
TFF Pharmaceuticals, Inc. (TFFP) Reports Q1 Loss, Tops Revenue Estimates
Arcellx, Inc. (ACLX) Reports Q1 Loss, Tops Revenue Estimates
LUMO: What are Zacks experts saying now?
Zacks Private Portfolio Services
UniQure (QURE) Reports Q4 Loss, Tops Revenue Estimates
Exact Sciences (EXAS) Reports Q4 Loss, Tops Revenue Estimates
Lumos Pharma (LUMO) Reports Q3 Loss, Lags Revenue Estimates
Other News for LUMO
Lumos Pharma Announces Abstract Accepted for Presentation at September Medical Meeting, SLEP 2024
Stocks with three weeks of improving technicals by Piper Sandler
Lumos Pharma to Participate in H.C. Wainwright 26th Annual Global Investment Conference
Analysts Offer Insights on Healthcare Companies: Lumos Pharma (LUMO) and Rani Therapeutics Holdings (RANI)
Analysts Offer Insights on Healthcare Companies: Oncolytics Biotech (ONCY), R1 RCM (RCM) and Lumos Pharma (LUMO)